Hyperion DeFi (NASDAQ:HYPD) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Hyperion DeFi (NASDAQ:HYPD) from a sell rating to a hold rating in a research report sent to investors on Saturday.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Hyperion DeFi in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Reduce” and a consensus price target of $2.00.

Hyperion DeFi Stock Up 2.0%

HYPD stock opened at $4.09 on Friday. The stock has a market cap of $33.12 million, a P/E ratio of -1.01 and a beta of 2.57. The company has a current ratio of 2.25, a quick ratio of 2.25 and a debt-to-equity ratio of 0.11. The stock’s fifty day simple moving average is $7.76 and its two-hundred day simple moving average is $7.30. Hyperion DeFi has a 1-year low of $0.85 and a 1-year high of $17.99.

Hyperion DeFi (NASDAQ:HYPD) last released its earnings results on Friday, November 14th. The company reported $0.05 EPS for the quarter. The company had revenue of $0.36 million for the quarter. Hyperion DeFi had a negative return on equity of 119.59% and a negative net margin of 62,238.41%. Analysts expect that Hyperion DeFi will post -41.6 EPS for the current year.

Institutional Investors Weigh In On Hyperion DeFi

A hedge fund recently bought a new stake in Hyperion DeFi stock. Virtu Financial LLC acquired a new stake in Hyperion DeFi, Inc. (NASDAQ:HYPD) in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 23,065 shares of the company’s stock, valued at approximately $25,000. Virtu Financial LLC owned 0.82% of Hyperion DeFi at the end of the most recent quarter. 25.84% of the stock is owned by institutional investors and hedge funds.

About Hyperion DeFi

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.